Program
PF-08049820
A development code. Also written as “PF-08049820 MR1”, “PF-08049820 MR2” and “PF-08049820 IR”.
In Pfizer's pipeline, STAT6 inhibitor
. Its studies are mostly in Dermatitis, Atopic, led by Pfizer.
Furthest: phase 2, since Oct 9, 20256 company-led studies, 1 open or runningNext primary completion: Feb 2, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 61 open or running | phase 2since Oct 9, 2025 | Nov 11, 2024 | Feb 2, 2028phase 2 · NCT07216027 |
- Named in Pfizer’s own pipeline as
PF-08049820
, phase 2, as of Nov 3, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 11, 2024First study: phase 1 study in Dermatitis, AtopicFirst studyNCT06686797 · 71 enrolled · United States
- Aug 28, 2025Phase 1 study in Dermatitis, AtopicNCT07172321 · 12 enrolled · United States
- Sep 2, 2025Phase 1 study in Dermatitis, AtopicNCT07190430 · 16 enrolled · United States
- Oct 9, 2025Phase 2 study in Dermatitis, AtopicNCT07216027 · 165 planned · United States, Bulgaria, Canada and more
- Nov 13, 2025Phase 1 study in Dermatitis, AtopicNCT07284173 · 18 enrolled · China
- May 12, 2026Phase 1 study in Healthy AdultsNCT07597928 · 24 enrolled · United States
Ahead
- Feb 2, 2028Primary completion: phase 2 study in Dermatitis, AtopicNCT07216027
TargetBeta
“STAT6 inhibitor”the company's pipeline, read by Claude · source
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07597928Healthy Adults · United States | 1 | Completed | Aug 7, 2026 | 24 |
| NCT07284173Dermatitis, Atopic · China | 1 | Completed | Dec 18, 2025 | 18 |
| NCT07216027Dermatitis, Atopic · United States, Bulgaria, Canada and more | 2 | Recruiting | Feb 2, 2028 | 165 |
| NCT07190430Dermatitis, Atopic · United States | 1 | Completed | Dec 15, 2025 | 16 |
| NCT07172321Dermatitis, Atopic · United States | 1 | Completed | Oct 4, 2025 | 12 |
| NCT06686797Dermatitis, Atopic · United States | 1 | Completed | Feb 23, 2026 | 71 |
How it is read
Names in the registry
- “PF-08049820”, 5 entries
- “PF-08049820 MR1”, 1 entry
- “PF-08049820 MR2”, 1 entry
- “PF-08049820 IR”, 1 entry
Codes read as this program: PF08049820.
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.